[ad_1]
Dr.Ci:Labo: Phenylethylresorcinol is better than vitamin C and niacinamide in treating hyperpigmentation
Dr.Ci:Labo claims new research on phenylethylresorcinol has demonstrated its high effectiveness in combating hyperpigmentation, exceeding the effectiveness of well-known ingredients such as vitamin C and niacinamide.
This is based on the research of Dr. CiLab’s new and improved 377VC Radiance Serum.
This serum was shown to improve transient UV-induced hyperpigmentation and skin whitening by 6 times over 7 days over a blank control group.
Colmar Korea develops sun care products using newly discovered lactic acid bacteria probiotics derived from the skin microbiome
Cosmetics company Colmar Korea has discovered a probiotic ingredient derived from the skin microbiome that it claims can reduce skin aging caused by ultraviolet (UV) rays.
The skin aging process is influenced by internal and external factors, such as exposure to UV rays, leading to photoaging, which manifests as skin problems such as wrinkles and discoloration.
The skin microbiome is a diverse community of microorganisms on the surface of the skin that plays an important role in barrier function and can be influenced by factors such as humidity and acidity (pH).
High BMI alters facial skin microbiome, impairs barrier function and increases risk of skin diseases – Chinese study
Chinese researchers have found that a high body mass index (BMI) alters the facial skin microbiome, affecting the integrity of the skin barrier and increasing the risk of skin diseases.
Obesity has been proven to be a major risk factor for inflammatory skin diseases, while the skin microbiome is a site influenced by biophysical properties such as moisture, sebum, and skin surface acidity (pH). It is known that specific microbial communities exist.
However, little is known about the association between BMI and facial skin physiological parameters, especially the facial skin microbiome.
Skin microbiome-based approaches to atopic dermatitis show promise, but further research is needed to confirm long-term results
Skin microbiome-based therapeutic strategies for atopic dermatitis (AD) may have more targeted effects, but further research is needed to investigate whether this approach leads to durable clinical results. “Robust research” is needed.
AD is a chronic inflammatory skin disease characterized by disruption of skin barrier function and immune dysregulation. Its onset usually occurs during childhood and is more common in children, affecting up to 25%.
Children with Alzheimer’s disease often experience complications such as food allergies, allergic rhinitis, asthma, autoimmune diseases, and recurrent skin infections.
Lucas Meyer Cosmetics’ latest peptide launch aims for “future-proof” skin
Ingredients company Lucas Meyer Cosmetics has introduced a new peptide that aims to tap into consumers’ desire to “future-proof” their skin from the effects of aging.
Corneopeptyl is the company’s latest patented peptide that claims biomimetic properties for the LCE6A protein.
It is part of the late cornification envelope protein family and is known to be essential for the mechanical resistance of corneocytes in the stratum corneum.
[ad_2]
Source link
